Baclofen is used for severe muscle spasticity linked to neurological disorders such as multiple sclerosis, spinal disease, and brain injury. Its active substance reduces abnormal signals in the…
Baclofen is used for severe muscle spasticity linked to neurological disorders such as multiple sclerosis, spinal disease, and brain injury. Its active substance reduces abnormal signals in the spinal cord, helping ease stiffness, spasms, and painful muscle contractions.
Baclofen is a centrally acting skeletal muscle relaxant for spasticity caused by disease or injury affecting the brain or spinal cord. Spasticity means persistent muscle tightness, exaggerated reflexes, and involuntary spasms. The product sold on this page is Baclofen in pill form. The active substance is baclofen.
The product sold on this page is Baclofen in pill form. The active substance is baclofen.
Baclofen is a centrally acting skeletal muscle relaxant for spasticity caused by disease or injury affecting the brain or spinal cord. Spasticity means persistent muscle tightness, exaggerated reflexes, and involuntary spasms. It can restrict walking, transfers, dressing, sleep, and personal care.
Doctors may prescribe Baclofen for:
Treatment aims to reduce excessive muscle activity without removing useful strength. A person who relies on some muscle tone for standing or transferring may become less stable if the dose is increased too quickly.
Spinal and brain diseases can disrupt the normal balance between signals that activate muscles and signals that relax them. Baclofen acts within the central nervous system, where these abnormal reflexes are coordinated. A peripheral muscle relaxant acts mainly at the muscle or neuromuscular junction and may not address the spinal reflex responsible for neurological spasticity.
Multiple sclerosis is one recognised setting in which spasticity can develop. Spinal cord lesions, cerebral palsy, stroke-related damage, and traumatic brain injury can also produce increased tone. NICE guidance on multiple sclerosis management describes antispasticity medicines as part of an individual treatment plan when stiffness or spasms impair function [3].
Baclofen should not be used in people with a known allergy to baclofen or any tablet component. Extra caution is required with kidney impairment, epilepsy, respiratory disease, sleep apnoea, severe liver disease, psychosis, or a history of falls.
Specific interaction concerns include:
Baclofen may not be suitable if you have kidney problems, epilepsy, breathing disease, sleep apnoea, severe liver disease, psychosis, or a history of falls. Tell the prescriber if you drink alcohol or take opioids, benzodiazepines, sleeping tablets, sedating antihistamines, other muscle relaxants, or medicines that affect alertness or blood pressure.
Pregnancy and breastfeeding require an individual risk assessment. The medicine should be used carefully in older adults because dizziness, weakness, confusion, and falls may occur with smaller changes in exposure.
Baclofen can cause drowsiness, dizziness, fatigue, weakness, nausea, headache, confusion, and reduced coordination. These reactions are more likely during treatment initiation or after a dose increase. Some people notice sedation within the first few doses, while others develop it only after accumulation over several days.
Common or clinically recognised reactions include:
The risk rises when Baclofen is combined with alcohol, opioid analgesics, sleeping tablets, sedating antihistamines, benzodiazepines, or other central nervous system depressants. Severe toxicity may produce profound sedation, hypotonia, slowed breathing, low blood pressure, seizures, coma, or death. The FDA prescribing information describes respiratory depression and coma among serious manifestations of overdose [2].
An overdose requires urgent medical assessment. Warning signs include extreme sleepiness, unusual confusion, limp muscles, vomiting while difficult to wake, slow or shallow breathing, loss of consciousness, or seizures.
Abrupt discontinuation can also cause serious problems. Withdrawal symptoms may include increased spasticity, agitation, hallucinations, fever, rapid heartbeat, seizures, muscle breakdown, and severe confusion. Sudden withdrawal has been associated with life-threatening complications, especially after prolonged treatment or high doses.
Baclofen is a GABA(_B) receptor agonist. GABA is an inhibitory neurotransmitter, meaning it reduces the likelihood that nerve cells will send activating signals. Baclofen strengthens this inhibitory signalling in the spinal cord and reduces the reflex activity that keeps affected muscles tight.
The medicine acts mainly on presynaptic and postsynaptic GABA(_B) receptors. Presynaptic activity decreases the release of excitatory neurotransmitters. Postsynaptic activity makes the receiving nerve cell less responsive to stimulation. The combined effect reduces both monosynaptic and polysynaptic reflexes.
The result is less involuntary muscle contraction.
A monosynaptic reflex uses a direct connection between sensory and motor nerve cells. A polysynaptic reflex uses one or more connecting nerve cells and can produce a wider, more sustained response. Baclofen suppresses both pathways at spinal level.
The product information for oral baclofen describes its GABA(_B)-mediated effects and warns that excessive central nervous system depression can occur with high exposure [1].
Several practical errors can reduce benefit or increase harm:
Different medicines reduce muscle spasm through different receptors or nervous-system pathways. The choice depends on the source of spasticity, muscle strength, daytime alertness, kidney function, blood pressure, and interaction risk.
| Medicine or category | Main pharmacological focus | Practical distinction |
|---|---|---|
| Baclofen | GABA(_B) receptor agonism | Commonly used for neurological spasticity from spinal or brain disease; sedation and weakness can occur |
| Tizanidine | Central alpha-2 adrenergic agonism | May reduce spasticity but can cause drowsiness, low blood pressure, dry mouth, and liver-related concerns |
| Clonidine and related central agents | Alpha-2 adrenergic activity | Used mainly for blood pressure or selected neurological indications; sedation and hypotension limit routine spasticity use |
Baclofen is often considered when spasticity originates in the spinal cord or central nervous system. Tizanidine may be selected when intermittent dosing is useful, though its blood-pressure effects and liver monitoring requirements can matter. Clonidine is not a routine substitute for Baclofen in standard spasticity management.
Other central nervous system medicines may be used for specific symptoms, such as neuropathic pain or anxiety, but they do not reproduce Baclofen’s GABA(_B) mechanism. Combining several sedating medicines can increase impairment without producing proportional relief.
In clinical practice, doctors often begin cautiously because the same reduction in muscle tone that eases a spasm can make standing or walking more difficult. The treatment goal is controlled movement, not complete loss of muscle tone.
A prescriber may ask about:
Kidney function deserves attention because baclofen is eliminated largely through the kidneys. Reduced clearance can increase exposure and make confusion, sedation, or toxicity more likely. The UK Medicines and Healthcare products Regulatory Agency product information for baclofen describes renal impairment and central nervous system depression as important clinical considerations [4].
Tell the prescriber about kidney disease, epilepsy, breathing problems, sleep apnoea, alcohol use, pregnancy, breastfeeding, and every medicine or supplement being taken. The FDA prescribing information reviewed in 2020 identifies central nervous system depression, renal impairment, and withdrawal as key safety issues. A doctor will also assess whether reducing muscle tone could worsen balance, transfers, or walking. The intended functional goal should be clear before the dose is adjusted.
Do not split, crush, or chew a Baclofen tablet unless the specific tablet design and prescription instructions permit it. The UK and Irish regulatory approach described in HPRA product information from 2021 depends on the formulation and tablet characteristics. Altering a tablet can make swallowing harder, change how the dose is delivered, or cause an inaccurate amount to be taken. A pharmacist can confirm the appropriate method for the exact tablet supplied.
Yes, drowsiness is a recognised effect of Baclofen. NHS clinical information reviewed in 2025 advises caution with driving and activities requiring alertness when treatment has started or the dose has changed. Dizziness, weakness, fatigue, and reduced coordination can occur alongside sleepiness. Alcohol and other sedatives can intensify this effect.
Some people notice reduced spasms within hours of an individual dose, while stable control may require gradual adjustment over days or longer. Clinical guidance from NICE in 2022 supports adjusting antispasticity treatment according to response, function, and adverse effects rather than judging the result after one dose. Improvement may first appear as easier movement, fewer night spasms, or less painful tightening. Persistent symptoms should lead to a treatment review rather than unsupervised dose escalation.
The combination can increase sleepiness, confusion, slowed breathing, and loss of coordination. The World Health Organization’s 2019 technical report on medication safety in polypharmacy describes additive central nervous system depression as a concern when sedating medicines are combined. Opioids, benzodiazepines, sleeping tablets, sedating antihistamines, and alcohol deserve specific attention. Any combination should be reviewed before treatment begins or when a new medicine is added.
The prescriber should reassess the diagnosis, dose schedule, adherence, kidney function, triggers, and other causes of spasms. The UK Medicines and Healthcare products Regulatory Agency’s 2023 baclofen product information supports reviewing benefit against tolerability when response is inadequate. Some people need a slower titration, while others require physiotherapy, stretching, treatment of pain, or a different antispasticity approach. Do not take extra Baclofen to force a response.
Regular Baclofen treatment should usually be reduced gradually rather than stopped abruptly. The FDA label from 2020 describes increased spasticity, hallucinations, seizures, fever, confusion, and other serious withdrawal effects after sudden discontinuation. A tapering plan depends on treatment duration, dose, neurological condition, and the reason for stopping. Urgent medical help is needed for severe rebound spasms, altered consciousness, seizures, or breathing difficulty.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
Based on 5 reviews
He used Baclofen at the prescribed dose for leg stiffness linked to multiple sclerosis for one week. After the dose was adjusted gradually, night spasms became less disruptive, although he felt sleepy for the first week.
One week 5 Nov 2026He took Baclofen at the prescribed dose for spinal-cord-related spasms for several days and found transfers from bed easier. He also noticed reduced leg strength and needed a slower titration than expected.
Several days 1 Nov 2026He used Baclofen at the prescribed dose for several days and reported less painful calf tightening after regular treatment. Early dizziness made driving unsuitable, so he changed the timing of his evening dose with medical guidance.
Several days 7 Oct 2026He took Baclofen at the prescribed dose for several weeks but stopped suddenly after feeling better and experienced a sharp increase in spasms, sweating, and anxiety. A supervised restart and gradual reduction were then required.
Several weeks 15 Oct 2026He used Baclofen at the prescribed dose for several weeks and found the tablets helpful for stiffness but developed marked confusion when another sedating medicine was added. Symptoms improved after the combination was reviewed.
Several weeks 23 Oct 2026
